References

For additional information, please see the below list of related reference materials. Items marked with an asterisk (*) have reprints available by contacting GTI Diagnostics at 262.754.1000.

Mace®1
MicroAMS®
PakAuto®
PakPlus®
Pak1®
PF4 Enhanced®
Quik-ID®
QuikScreen®

Mace®1 ^

Kowalski MA, Moghaddam M. “Evaluation of GTI-Modified Antigen Capture Elisa (Mace) for the Detection of IgG Antibodies to Platelet and HLA Antigens.” 5th European Symposium on Platelet and Granulocyte Immunobiology, May 9-12, 1998, S’Agaro, Girona, Spain.

MicroAMS® ^

Raposa J, Black J, Wolfe K, Lorber M, Cuchara L, “The Use of the GTI Transplant Monitoring System (TMS) in Predicting CI & CII Alloreactivity.” Surgery-Histocompatibility & Immune Evaluation Lab, Yale University School of Medicine, New Haven, CT, USA.

Pressman M1, Chance S1, Adams P2, Orosz C3, Phelan D4, Mohanakumar T5, “Performance of the GTI Antibody Monitoring System: HLA Class I and Class II.” 1Product Development, GTI, Inc., Waukesha, WI, USA; 2Transplant Laboratory, Ohio State University Medical Center, Columbus, OH, USA; 3Department of Surgery, Ohio State University Medical Center, Columbus, OH, USA; 4Transplant Laboratory, Barnes-Jewish Hospital, St. Louis, MO, USA; 5Department of Surgery, Washington University, St. Louis, MO, USA.

Adams PW, Orosz CG. “Rituximab Does Not Interfere in Donor-Specific MHC TAMS (ELISA) Assay.” Clinical Histocompatibility Laboratory, Ohio State University Medical Center, Columbus, OH, USA, American Samoa.

Adams PW1, Graziani J2, Orosz C3, Zachary AA4. “A Donor-Specific ELISA for Monitoring Antibody Down-Regulation.” 1Surgery, Ohio State University, Columbus OH, USA; 2Medicine, John Hopkins University School of Medicine, Baltimore, MD, USA.

Book BK, Agarwal A, Milgrom AB, Bearden CM, Sidner RA, Higgins NG, Pescovitz MD. “New Crossmatch Technique Eliminates Interference by Humanized and Chimeric Monoclonal Antibodies.” Transplatation Proceedings 2005, 37: 640-642.

Magro CM, Klinger DM, Adams PW, Orosz CG, Pope-Harman AL, Waldman WJ, Knight D, Ross Jr P. “Evidence That Humoral Allograft Rejection in Lung Transplant Patients Is Not Histocompatibility Antigen-Related.” Am J Transplatation 2003, 3: 1264-1272.

Adams PW, Pelletier RP, Gullett JF, Orosz CG. “Post-Transplant Detection of Donor-Reactive Alloantibodies by TMS (ELISA) Correlates with Adverse Clinical Outcome.” Surgery, OSUMC, Columbus, OH, USA.

Yang CW, Oh EJ, Lee SB, Moon IS, Kim DG, Choi BS, Park SC, Choi YJ, Park YJ, Han K. “Detection of Donor-Specific Anti-HLA Class I and II Antibodies Using Antibody Monitoring System.” Transplant Proc 2006, 38:9: 2803-2806.

Altermann WW, Seliger B, Sel S, Wendt D, Schlaf G. “Comparison of the Established Standard Complement-Dependent Cytotoxicity and Flow Cytometric Crossmatch Assays with a Novel ELISA-Based HLA Crossmatch Procedure.” Histol Histopathol 2006, 21: 1115-1124

PakAuto® ^

Davoren A, Bussel J, Curtis BR, Moghaddam M, Aster RH, McFarland JG. “Prospective Evaluation of a New Platelet Glycoprotein (GP)-Specific Assay (PakAuto) in the Diagnosis of Autoimmune Thrombocytopenia (AITP).” Am J Hematol 2005, 78: 193-197.

PakPlus® ^

Shivji S, Halpin A, Morrison D. “Incidence of HLA Class I Antibodies and Platelet Antibodies Detected by ELISA in Platelet Antibody Investigations.” Histocompatibility Laboratory, University of Alberta Hospital, Edmonton, Alberta, Canada.

Moore SB, DeGoey S. “Serum Platelet Antibody Testing: Evaluation of Solid-Phase Enzyme Immunoassay and Comparison With Indirect Immunofluorescence.” Am J Clin Pathol 1998, 109:2: 190-195.

Davoren, et. al. “Antenatal screening for human platelet antigen-1a: Results of a prospective study at a large maternity hospital in Ireland.” British Journal of Obstetrics and Gynecology 2003, 110: 492-496.

Pak1® ^

PF4 Enhanced® ^

Collins JL, Aster RH, Moghaddam M, Piotrowski MA, Strauss TR, McFarland JG. “Diagnostic Testing for heparin-induced thrombocytopenia (HIT): An enhanced platelet factor 4 complex enzyme linked immunosorbent assay (PF4 Elisa).” Blood (Suppl 1) 1997, 90:10.

Zwicker JI, Uhl L, Huang W-Y, Shaz BH, Bauer KA. “Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.” J Thromb Haemost 2004, 2: 2133-2137.

Francis JL, Palmer GJ, Moroose R, Drexler, A. “Comparison of Bovine and Porcine Heparin in Heparin Antibody Formation After Cardiac Surgery.” Ann Thorac Surg 2003, 75: 17-22.

*Rice L, Attisha WK, Drexler A, Francis JL. “Delayed-Onset Heparin-Induced Thrombocytopenia.” Ann Intern Med 2002, 136: 210-215.

Shaheed G, et. al. “PF4 Enhanced assay for the diagnosis of heparin-induced thrombocyotpenia in complex medical and surgical patients.” Crti Care Med 2007, 35:7: 1-5.

Quik-ID® ^

*Zachary AA, Ratner LE, Graziani JA, Lucas DP, Delaney NL, Leffell MS. “Characterization of HLA Class I Specific Antibodies by ELISA Using Solubilized Antigen Targets: II. Clinical Relevance.” Human Immunology 2001, 62: 236-246.

*Zachary AA, Delaney NL, Lucas DP, Leffell MS. “Characterization of HLA Class I Specific Antibodies by ELISA Using Solubilized Antigen Targets: I. Evaluation of the GTI QuikID Assay and Analysis of Antibody Patterns.” Human Immunology 2001, 62: 228-235.

Griffiths EJ, Nelson RE, Dupont PJ, Warrens AN. “Skewing of Pretansplant Anti-HLA Class I Antibodies of Immunoglobulin G Isotype Solely Toward Immunoglobulin G1 SubClass is Associated with Poorer Renal Allograft Survival.” Transplantation 2004, 77: 1771-1773.

*Zachary AA, Ratner LE, Leffell MS. “Low Levels of HLA-Specific Antibody: Relevance, Detection, and Treatment.” Transplantation Proceedings 2001, 33: 469-470.

QuikScreen® ^

Petraroia R1, Collins D1, McGee M1, Crawford J1, Schmitz J2. “Evaluation of Automated HLA Class I ELISA Antibody Screening Using the Biotest QuickStep ELISA Processor.” 1McLendon Clinical Laboratories, UNC Hosptials, chapel Hill, NC, USA; 2Pathology & Laboratory Medicine, UNC Chapel Hill, Chapel Hill, NC, USA.

Panigrahi A, Deka R, Bhowmik D, Tiwari SC, Mehra NK. “Immunological Monitoring of Posttransplant Allograft Sensitization Following Living Related Donor Renal Transplantation.” Transplantation Proceedings 2004, 36: 1336-1339.

Aragao E, Moura LA, Pacheco-Silva A. “Monitoring Anti-HLA Class I IgG Antibodies in Renal Transplant Recipients.” Transplantation Proceedings 2004, 36: 836-837.

Moore SB, Ploeger NA, DeGoey SR. “HLA Antibody Screening: Comparison of a Solid Phase Enzyme-Linked Immunoassay with Antiglobulin-Augmented Lymphocytotoxicity.” Transplantation 1997, 64: 1617-1619.

*Lucas DP, Paparounis ML, Myers L, Hart JM, Zachary AA. “Detection of HLA Class I-Specific Antibodies by the QuikScreen Enzyme-Linked Immunosorbent Assay.” Clin Diagn Lab Immunol 1997, 4: 252-257.